Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001144204-17-046387
Filing Date
2017-09-01
Accepted
2017-09-01 16:04:24
Documents
7
Period of Report
2017-10-19
Effectiveness Date
2017-09-01

Document Format Files

Seq Description Document Type Size
1 DEF 14A v474379_def14a.htm DEF 14A 220281
2 GRAPHIC line.gif GRAPHIC 43
3 GRAPHIC logo_protalix.jpg GRAPHIC 25457
4 GRAPHIC sig_yossi-maimon.jpg GRAPHIC 9221
5 GRAPHIC spacer.gif GRAPHIC 43
6 GRAPHIC v474379_proxycard-1.jpg GRAPHIC 805331
7 GRAPHIC v474379_proxycard-2.jpg GRAPHIC 318010
  Complete submission text file 0001144204-17-046387.txt   1816882
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 171066395
SIC: 2836 Biological Products, (No Diagnostic Substances)